These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34611996)

  • 21. Casebook consults: improving outcomes in gout (multimedia activity).
    Doghramji PP; Mandell BF; Pope RS
    Am J Med; 2012 Aug; 125(8):S1. PubMed ID: 22840678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A survey of the assessment and management of gout in general practitioners and medical officers within the Illawarra Network, Australia.
    Terrill M; Riordan J
    Int J Rheum Dis; 2017 Aug; 20(8):990-995. PubMed ID: 27153502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stopping progression to tophaceous gout. When and how to use urate-lowering therapy.
    McDonald E; Marino C
    Postgrad Med; 1998 Dec; 104(6):117-20, 123-4, 127. PubMed ID: 9861261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Barriers to Care in Gout: From Prescriber to Patient.
    Vaccher S; Kannangara DR; Baysari MT; Reath J; Zwar N; Williams KM; Day RO
    J Rheumatol; 2016 Jan; 43(1):144-9. PubMed ID: 26568590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gout in Native Hawaiian Patients in Hawai'i: Clinical Characteristics and Disparities.
    Chang C; Siu A; Kimata C; Sawada H; Mak VP; Lim SY
    Arthritis Care Res (Hoboken); 2024 May; 76(5):712-719. PubMed ID: 38163751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of gout in a South Auckland general practice.
    Reaves E; Arroll B
    J Prim Health Care; 2014 Mar; 6(1):73-8. PubMed ID: 24624415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential unmet need for gout diagnosis and treatment: capture-recapture analysis of a national administrative dataset.
    Jackson G; Wright C; Thornley S; Taylor WJ; Te Karu L; Gow PJ; Arroll B; Gribben B; Dalbeth N; Winnard D
    Rheumatology (Oxford); 2012 Oct; 51(10):1820-4. PubMed ID: 22723595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patients and providers view gout differently: a qualitative study.
    Harrold LR; Mazor KM; Velten S; Ockene IS; Yood RA
    Chronic Illn; 2010 Dec; 6(4):263-71. PubMed ID: 20675361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A qualitative study to explore health professionals' experience of treating gout: understanding perceived barriers to effective gout management.
    Humphrey C; Hulme R; Dalbeth N; Gow P; Arroll B; Lindsay K
    J Prim Health Care; 2016 Jun; 8(2):149-56. PubMed ID: 27477557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive dietary education in treated gout patients does not further improve serum urate.
    Holland R; McGill NW
    Intern Med J; 2015 Feb; 45(2):189-94. PubMed ID: 25495503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inpatient rheumatology consultation for gout flares and advice to initiate urate lowering treatment (ULT) in hospital discharge summary increases ULT prescription in primary care.
    Kapadia A; Abhishek A
    Joint Bone Spine; 2019 Mar; 86(2):271-272. PubMed ID: 29966768
    [No Abstract]   [Full Text] [Related]  

  • 32. The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach.
    Lindsay K; Gow P; Vanderpyl J; Logo P; Dalbeth N
    J Clin Rheumatol; 2011 Jan; 17(1):1-6. PubMed ID: 21169857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
    Tausche AK; Christoph M; Forkmann M; Richter U; Kopprasch S; Bielitz C; Aringer M; Wunderlich C
    Rheumatol Int; 2014 Jan; 34(1):101-9. PubMed ID: 24026528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study.
    Pisaniello HL; Lester S; Gonzalez-Chica D; Stocks N; Longo M; Sharplin GR; Dal Grande E; Gill TK; Whittle SL; Hill CL
    Arthritis Res Ther; 2018 Jul; 20(1):143. PubMed ID: 29996922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare.
    Janssen CA; Oude Voshaar MAH; Ten Klooster PM; Vonkeman HE; van de Laar MAFJ
    Clin Rheumatol; 2019 Aug; 38(8):2233-2239. PubMed ID: 31030363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
    Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
    BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population-specific association between ABCG2 variants and tophaceous disease in people with gout.
    He W; Phipps-Green A; Stamp LK; Merriman TR; Dalbeth N
    Arthritis Res Ther; 2017 Mar; 19(1):43. PubMed ID: 28270222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
    Corbett EJM; Pentony P; McGill NW
    Int J Rheum Dis; 2017 Jul; 20(7):894-897. PubMed ID: 28205336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gout.
    Dalbeth N; Choi HK; Joosten LAB; Khanna PP; Matsuo H; Perez-Ruiz F; Stamp LK
    Nat Rev Dis Primers; 2019 Sep; 5(1):69. PubMed ID: 31558729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The management of gout at an academic healthcare center in Beijing: a physician survey.
    Fang W; Zeng X; Li M; Chen LX; Schumacher HR; Zhang F
    J Rheumatol; 2006 Oct; 33(10):2041-9. PubMed ID: 17014019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.